1 reports of this reaction
11.1% of all LYTTA VESICATORIA reports
#5 most reported adverse reaction
HEPATIC FUNCTION ABNORMAL is the #5 most commonly reported adverse reaction for LYTTA VESICATORIA, manufactured by SEVENE USA. There are 1 FDA adverse event reports linking LYTTA VESICATORIA to HEPATIC FUNCTION ABNORMAL. This represents approximately 11.1% of all 9 adverse event reports for this drug.
Patients taking LYTTA VESICATORIA who experience hepatic function abnormal should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC FUNCTION ABNORMAL is a frequently reported adverse event for LYTTA VESICATORIA, accounting for a significant proportion of all reports.
In addition to hepatic function abnormal, the following adverse reactions have been reported for LYTTA VESICATORIA:
The following drugs have also been linked to hepatic function abnormal in FDA adverse event reports:
HEPATIC FUNCTION ABNORMAL has been reported as an adverse event in 1 FDA reports for LYTTA VESICATORIA. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC FUNCTION ABNORMAL accounts for approximately 11.1% of all adverse event reports for LYTTA VESICATORIA, making it a notable side effect.
If you experience hepatic function abnormal while taking LYTTA VESICATORIA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.